Objective: To prospectively evaluate the survival benefit of dissection of the nerve plexus and lymphadenectomy in patients with pancreatic head cancer. Background: Despite randomized controlled trials on the extent of surgery in pancreatic cancer, attempts have been made to perform more extended resections. Methods: A total of 244 patients were enrolled; of these, 200 were randomized to undergo standard resection or extended resection, with the latter including the dissection of additional lymph nodes and the right half of the nerve plexus around the superior mesenteric artery and celiac axis. We evaluated 167 patients from 7 centers who fulfilled all of the required criteria. Result: Operation time was longer and estimated blood loss was higher in the extended resection group than in the standard resection group, but the R0 resection rate was comparable. The mean number of lymph nodes retrieved per patient was higher in the extended resection group than in the standard resection group (33.7 vs 17.3; P < 0.001). The morbidity rate was slightly higher in the extended resection group than in the standard resection group. Two patients in the extended resection group died in hospital. Median survival after R0 resection was similar in the extended resection and standard resection groups (18.0 vs 19.0 months; P = 0.239) regardless of lymph node metastasis. Adjuvant chemoradiation had a positive impact on overall survival. Conclusions: This study suggests that extended lymphadenectomy with dissection of the nerve plexus does not provide a significant survival benefit compared with standard resection in pancreatic head cancer. Standard resection can be performed safely and efficiently, without negatively affecting From the oncologic efficacy or long-term survival, when compared with extended pancreaticoduodenal resection. (NCT00679913)?
P ancreatic cancer remains one of the most aggressive and lethal malignancies worldwide, and it is the fourth leading cause of cancer-related deaths in Western countries. 1 Furthermore, it is an important cancer type in Asian countries, where its incidence and lethality have been steadily increasing. 2, 3 Despite recent improvements in treatment modalities, pancreatic cancer remains a devastating disease for which there is no definitive treatment except surgical resection. However, at initial diagnosis of the disease, only 15% to 25% of patients with pancreatic cancer are eligible for curative resection. 4, 5 Efforts have been made to enhance resectability and survival using aggressive extended resection, including extended lymphadenectomy and dissection of the nerve plexus around major vessels. [6] [7] [8] Randomized controlled studies have found that despite its theoretical advantages, extended pancreatectomy does not have survival advantages compared with standard pancreatectomy. [9] [10] [11] [12] [13] [14] [15] [16] However, previous randomized controlled trials (RCTs) have had limitations such as small numbers of patients, the lack of an objectively shown operating field, the absence of a statistical determination of the required number of patients, the inclusion of patients with nonpancreatic ductal adenocarcinoma, and different extents of clearance of retroperitoneal tissue/nerve plexus and lymph nodes.
Because many pancreatic surgeons regard extended pancreatectomy to be better than standard pancreatectomy, additional welldesigned RCTs are needed, with larger sample sizes and standardized surgical methods of operation, focusing on the dissection of the nerve plexus and lymph nodes. We therefore compared standard with extended pancreatectomy, including lymphadenectomy with dissection of the nerve plexus, in the resection of ductal adenocarcinomas at the head of the pancreas.
Inclusion and Exclusion Criteria
Patients were included if they (1) were 20 to 85 years of age; (2) had no history of cancer including pancreatic cancer; (3) had a Karnofsky performance score above 70; (4) had potentially curable ductal adenocarcinoma of the pancreatic head (stage I or II), as shown by preoperative imaging (computed tomography, magnetic resonance imaging, and positron emission tomography); and (4) provided written informed consent. After enrollment, some patients were excluded because of (1) unresectable condition or metastasis found during surgery, (2) surgical rule violation, (3) inadequate case report form, or (4) pathologic diagnosis other than conventional ductal adenocarcinoma.
Participating Hospitals
Initially, 18 hospitals agreed to participate in this study. Patients were ultimately enrolled from 7 tertiary referral hospitals, which submitted case report forms without rule violation. All operations were performed by 17 surgeons specializing in pancreatic surgery.
Randomization and Data Management
After confirming patient eligibility, patients were randomized 1:1 to standard or extended pancreatoduodenectomy, using a Webbased system just before surgery. The allocation sequence was computer generated and randomly stratified by surgeon.
After randomization, all clinical and pathologic data, including operation field photographs, were uploaded and stored in a central database (https://mrcc.snuh.org/). All serious adverse events were submitted to the Clinical Trials Unit, Seoul National University Hospital, Seoul, Korea, and evaluated periodically by an independent data and safety monitoring board blinded to the treatment groups.
Surgical Procedures and Standardization
Pylorus-preserving pancreatoduodenectomy was defined as the standard procedure, although classical pancreatoduodenectomy was allowed, depending on the clinical situation. In standard resection, lymph nodes around the pancreas head (LN 13, 17) and gallbladder (LN 12c) were removed without nerve dissection around the hepatic artery or superior mesenteric artery (SMA). During extended resection, lymph nodes around the common hepatic artery (LN 8), celiac axis (LN 9), peripancreatic area (LN 13, 17), hepatoduodenal ligament (LN 12), SMA (LN 14), and para-aortic area (LN 16) between the celiac axis and the inferior mesenteric artery were dissected. All soft tissues around the hepatoduodenal ligament were completely dissected and skeletonized. The nerve plexus or ganglion on the right side of the celiac axis and SMA was dissected semicircumferentially. Differences in the extent of resection are summarized in Table 1 .
The surgical extent of standard and extended resection was determined by the participating surgeons, all of whom performed more than 30 pancreatoduodenectomies per year. This group met 4 times before the start of patient enrollment and adjusted detailed operation techniques. Photographs of surgical fields were taken after resection and uploaded into the central database (https://mrcc.snuh.org/) to verify the optimal extent of surgery in each group (Fig. 1) . These photographs were reviewed by the study committee of Seoul National University Hospital.
Adjuvant Treatment After Resection
Chemoradiation and maintenance chemotherapy were recommended for all patients except for those with a T1N0 lesion and no residual tumor, those with poor performance status or organ dysfunction, and those who refused adjuvant treatment. External beam radiation therapy was administered at a total dose of 45 Gy in 25 fractions 5 days per week for 5 weeks, with a tumor bed boost of 5.4 Gy in 3 fractions every other day. 5-Fluorouracil (5-FU) was administered concomitantly during radiotherapy as a radiosensitizer. Maintenance chemotherapy consisted of 6 cycles of 5-FU (375-500 mg/m 2 per day) every 4 weeks or 4 cycles of gemcitabine (1000 mg/m 2 ) every 3 weeks. 
Study Endpoints and Patient Numbers
The primary endpoint of this study was 2-year overall survival (OS) rate. Our trial was powered for superiority of survival data at 2 years according to the operation, assuming that the 2-year survival rate (37%) of patients who underwent extended pancreatectomy was 17% higher than that of the standard group (20%). Enrolling 224 patients would therefore provide 80% power to detect the superiority of a procedure with a 1-sided α = 0.05, β = 0.2, and an expected dropout rate of 30%, as determined by the Freedman formula. During recruitment, we added an additional 20 patients because of the high dropout rate (>30%); this change was accepted by the data controlling center and participating surgeons. The secondary endpoints were 2-year disease-free survival (DFS) rate and 5-year OS rate. 
Statistical Analysis
Patients who underwent the operation to which they were originally allocated and satisfied the criteria for optimal surgery based on photographs uploaded to our data center were evaluated. Results are presented as mean ± standard error of the mean. Nominal data were compared using χ 2 tests and continuous variables using Student t tests. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank test. Only variables statistically significant by univariate analysis were included in the multivariate analysis, which was performed using a Cox proportional hazards regression model. All statistical analyses were performed using SPSS, version 18.0 (SPSS Inc, Chicago, IL), with 2-sided P values less than 0.05 considered statistically significant.
RESULTS

Patient Enrollment and Demographic Findings
Between June 2006 and November 2009, a total of 244 patients were enrolled in this study, after excluding the 9 patients who refused to participate after initial agreement. After enrollment, 44 patients were excluded because of having unresectable or metastatic tumors, as determined intraoperatively ( Fig. 2 ).
Of the remaining 200 patients, 101 were randomized to standard pancreatectomy and 99 to extended pancreatectomy. Of these, 31 patients were excluded because of (1) having a nonductal adenocarcinoma (n = 8), such as intraductal papillary mucinous carcinoma or adenosquamous carcinoma; (2) having undergone inadequate surgery, as revealed by reviewing the photograph of the surgical field (n = 13); or (3) having inadequate case report forms (n = 10). We therefore evaluated a total of 169 patients, 83 in the standard group and 86 in the extended group. The 2 groups were well matched for mean age, sex distribution, operation type (pylorus-preserving pancreatoduodenectomy or classical pancreatoduodenectomy), resection rate of the portal vein, and follow-up duration ( Table 2) . Operation time was 64 minutes longer in the extended group than in the standard group, with estimated blood loss greater in the extended group (563.0 ± 56.3 mL) than in the standard group Table 2 shows the pathologic characteristics of the 2 groups. Although the percentage of patients with positive margins was slightly higher in the standard group (14.5%) than in the extended group (9.3%), the difference was not statistically significant. We also observed no between-group differences in tumor size, T stage, lymph node metastasis rate, and AJCC (American Joint Committee on Cancer) stage. Although the total number of retrieved lymph nodes was significantly lower in the standard group (17.3 ± 10.6) than in the extended group (33.7 ± 15.1) (P < 0.001), there was no betweengroup difference in the number of metastatic lymph nodes. The lymph node ratio was significantly higher in the standard group (0.15 ± 0.19) than in the extended group (0.09 ± 0.11) (P = 0.012).
Pathologic Differences Between the 2 Groups
Morbidity and Mortality
Morbidity was slightly higher in the extended group than in the standard resection group, although the difference was not statistically significant (43% vs 32.5%; P = 0.160) ( Table 3 ). In addition, there were no significant differences between detailed complication rates and surgical extent. Only 13 of the 86 patients (15.1%) in the extended resection group experienced postoperative diarrhea, indicating that right-sided 180-degree dissection of the nerve plexus had little effect on intestinal motility. None of the patients in the standard group died postoperatively compared with 2 patients in the extended group, 1 died of pneumonia and 1 died of sepsis associated with an SMA pseudoaneurysm.
Survival Data and Recurrence
After excluding the 2 patients who died postoperatively, the median OS of the enrolled patients was 18.7 months and the 2-, 3-, and 5-year OS rates were 39.9%, 25.8%, and 18.8%, respectively. There were no between-group differences in the OS (Fig. 3A) and DFS rates. The 2-year OS rate and the median survival of the standard group were 44.5% and 18.8 months, respectively, slightly higher than those of the extended group, which were 35.7% and 16.5 months, respectively; however, neither of these variables differed significantly between the groups (P = 0.401).
The primary endpoint of the study, the 2-year OS rate, was 44.5% (standard error = 5.5%) in the standard group and 35.7% (standard error = 5.2%) in the extended group {difference in 2-year OS rate [95% lower confidence interval (CI): −8.8 to −21.25; 1-sided P = 0.1225]}. The lower CI was within the noninferiority margin and thus the result for the 2-year OS rate met the criteria for noninferiority of extended versus standard resection (noninferiority margin: %)
Intention-to-treat analysis, which included all patients randomly assigned to the standard (n = 101) and extended (n = 99) groups, yielded similar results. The 2-year OS rate of the standard and extended groups was 46.1% and 36.4% (P = 0.285), respectively, and their median OS values were 19.0 and 18.0 months, respectively.
There were no survival differences between patients who were positive and those who were negative for lymph node metastases (Fig. 3B ). The median OS of patients with lymph node metastases who underwent extended surgery was 18 months, similar to 17.4 months of the standard group (P = 0.566) (Fig. 3B) .
Median OS was longer for the 122 patients who received adjuvant chemoradiation than for the 45 patients who did not (20. 14.0 months). The benefits of adjuvant treatment were especially prominent in the standard group (P = 0.016; Fig. 3C ).
There were no differences in the pattern and time of recurrence in the standard and extended groups (Table 4 ). Interestingly, during follow-up, peritoneal seeding was more frequently detected in the extended group than in the standard group (25.9% vs 8.3%; P = 0.011).
Prognostic Factors
Univariate analyses showed that poor tumor differentiation, the presence of endovascular tumor emboli in resected specimens, and the absence of postoperative adjuvant therapy were associated with adverse outcomes ( Table 5 ). In a multivariate Cox proportional hazards model, all 3 remained statistically significant: histologic differentiation [hazard ratio (HR), 3.847; 95% CI, 1.296-11.416; P = 0.015], endovascular tumor emboli (HR, 1.634; 95% CI, 1.129-2.363; P = 0.009), and adjuvant treatment (HR, 1.738; 95% CI, 1.156-2.612; P = 0.008).
DISCUSSION
In an effort to overcome the dismal results typically achieved among patients with pancreatic cancer, many surgeons perform more aggressive surgery, including extensive dissection of lymph nodes, the nerve plexus, and combined vascular resection. This approach has been supported by retrospective analyses showing that larger tumor negative margins are associated with longer survival in these patients. [6] [7] [8] [17] [18] [19] RCTs, however, are needed to determine the effect of extended surgery on survival in patients with pancreatic cancer. Surgery on the pancreas entails more delicate procedures than surgery on other gastrointestinal organs, providing several options for pancreatectomy. As a result, different types of operations have been described using the same terminology, making it difficult to compare the results of studies assessing the effect of surgical extent on survival. Despite these obstacles, 4 RCTs have assessed the effect of extended pancreatectomy on survival in patients with pancreatic cancer, but all failed to establish its superiority. [9] [10] [11] [12] [13] [14] [15] [16] Consistent with this, the findings of the present study indicated that extended pancreatectomy had no survival benefit.
One trial found no differences in morbidity, mortality, and survival between groups of patients undergoing standard (n = 40) and extended (n = 40) surgical procedures, although results suggested prolonged survival in node-positive patients who underwent extended pancreatectomy. 9 In another trial, 294 patients with periampullary lesions were randomized to undergo standard or extended surgery but only 57% had tumors of pancreatic origin. 10 Mortality and survival rates were comparable, whereas morbidity rates were significantly higher in the extended resection group (29% vs 43%; P < 0·010). In addition to evaluating patients of mixed pathology, the extended group in that trial underwent different types of surgery, such as distal gastrectomy, which may have affected morbidity rates. These 2 studies in Western countries were criticized for a lack of sufficient retroperitoneal clearance and an absence of dissection of the nerve plexus, both of which have been stressed during surgery for pancreatic cancer. 7, 8, 19, 20 A report from the Mayo Clinic may be the only Western study accepted by aggressive Japanese surgeons. 11 In that RCT, 40 patients underwent standard surgery and 39 underwent extended surgery. The mean number of resected lymph nodes was greater in the extended group (36 vs 15), but morbidity and mortality rates were comparable, as were 1-, 3-, and 5-year OS rates. Some patients in that trial underwent 360-degree circumferential dissection of the nerve plexus around the celiac axis and SMA, an approach that had the inevitable outcome of intractable diarrhea. Concerns about nutritional and immunologic problems in those patients may have affected their quality of life and survival.
A recent Japanese RCT yielded similar morbidity and survival results as the RCT from the Mayo Clinic. 12 Interestingly, the Japanese trial did not include adjuvant treatments for fear of masking the effects of surgical treatment despite some ethical problems.
The results of these 4 RCTs could not be directly compared because of the lack of uniformity of their protocols for lymphadenectomy and the extent of dissection of the nerve plexus around the celiac axis and SMA. Moreover, 3 of these studies enrolled only 40 or 50 patients per arm and did not calculate the minimum number of patients required under their statistical assumptions. An RCT designed to determine the potential survival benefit of lymphadenectomy would require too many patients to be practical. 13, 21 Besides lymphadenectomy, dissection of the nerve plexus has been considered important in increasing R0 resection and reducing local recurrence. 19, 20, 22 Both extrapancreatic nerve plexus and perineural invasion have been found prognostic in patients with pancreatic head cancer. 20 The extent of optimal dissection of the nerve plexus remains unclear. Although total circumferential dissection of the nerve plexus around the celiac axis and SMA was frequently performed, especially in Japan, 23 it may result in intractable diarrhea, malnutrition, and lower quality of life, which may have adverse effects on patient survival after extended pancreatectomy.
Of the 4 RCTs, 2 considered circumferential dissection of the nerve plexus a requisite procedure. 11, 12 Both trials reported that this type of extended resection reduced patient quality of life, primarily due to high rates of postoperative diarrhea with resulting malnutrition. To minimize the adverse effects of total circumferential nerve dissection, right-sided 180-degree dissection of the nerve plexus has been widely used in Japan. 20, 23, 24 New trials are needed to determine whether adjustment of the extent of nerve dissection can avoid nutritional and functional deterioration.
Another important concern is the standardization or uniformity of surgical procedures performed by surgeons participating in clinical trials, especially multicenter trials. The inspection and objective recording of surgical fields are needed to reduce any intentional or unintentional misgrouping of enrolled patients.
To overcome the limitations of previous RCTs, we designed and performed an RCT that assessed the extent of pancreatectomy for pancreatic ductal adenocarcinoma before the Japanese data were published. Beginning in 2005, quarterly board meetings of the Korean Pancreas Study Club were held to determine the extent of surgery and methods to qualify it. We began enrolling patients in 2006. To maintain the quality of the study and to optimize enrollment, we held board meeting every 4 months.
Although the incidence of R0 resection and the number of retrieved lymph node were higher in the extended group than in the standard group, there were no differences in OS or DFS. Extended surgery was not associated with survival benefits relative to standard surgery in any of our patient subgroups, even in those with lymph node metastases.
Although the number of retrieved lymph nodes was almost 2-fold higher in the extended group than in the standard group, the number of positive lymph nodes was similar and the lymph node ratio of the extended group (0.09 ± 0.11) was lower than that of the standard group (0.15 ± 0.19). In addition to having no survival benefits, the removal of regional lymph nodes was unnecessary.
We also assessed the optimal dissection of the nerve plexus around the celiac axis and SMA. Perineural invasion frequently occurs around major vessels and is prognostic for survival in patients with pancreatic cancer. 7, 8, 23, 25 Although the significance of nerve dissection around the major vessels adjacent to the pancreas head has been emphasized, 23, 24 the optimal extent and therapeutic benefits of nerve dissection around the celiac axis and SMA have not yet been clarified.
Previous RCTs did not have uniform criteria for nerve dissection, although 2 trials, one from the Mayo Clinic 11 and the other from Japan, 12 included circumferential dissection of the nerve plexus around the celiac axis and SMA. Those procedures, however, were associated with intractable diarrhea, resulting in chronic malnutrition and functional loss, which may have a negative effect on patient survival. In contrast, we dissected the right half of the nerve plexus, minimizing these procedure-associated adverse events. 23, 24 We found that the rate of postoperative diarrhea at 3 months was similar in the standard (12%) and extended (15%) groups, with none of these patients having severe intractable diarrhea. Although the morbidity and mortality rates were similar in the 2 groups, an SMA aneurysm, an procedure-specific complication, was observed in 2 patients in the extended group. One patient with bleeding from an SMA aneurysm died of related sepsis. Nerve dissection around the major vessels could increase operative risk, indicating the need for caution during these procedures.
Although there was no statistical difference between the 2 groups, hospital stay was 3 days longer in the extended group than in the standard group. Two patients in the extended group died in hospital, and the complication rate was slightly higher in the extended group, which may have been associated with the longer hospital stay. Hospital stay in our study was slightly longer than that in previous studies. Prolonged hospitalization is mainly caused by the low costs of hospitalization in Korea, with national health insurance paying for 95% of hospital fees for cancer patients. Because of these low medical costs, patients are reluctant to be discharged until they fully recover after surgery. According to a study by the Korean government, the average hospital stay after surgery for pancreatic cancer is 30.5 days.
We observed that patients who underwent nerve dissection did not show a survival benefit compared with patients of the standard group. Similarly, the results of the RCTs from the Mayo Clinic and Japan found that dissection of the nerve plexus had no therapeutic benefit regardless of the extent of dissection.
In this study, we did not randomize the patients considering adjuvant chemoradiation. Of our 169 patients, 122 (72.2%) received adjuvant chemoradiation, followed by maintenance chemotherapy. The role of radiation therapy remains somewhat inconclusive, but chemoradiation is a standard, often-used option for patients in both Korea and the United States. 26 Because of the limitations of national insurance guidelines for patients with resectable pancreatic cancer, more than 90% of chemotherapy-treated patients received 5-FU-based chemotherapy. In Korea, national health insurance pays only for some chemotherapeutic drugs. New chemotherapeutic drugs are allowed, but their costs must be covered by the patient. In Korea, 5-FU has been designated a primary chemotherapeutic agent for resectable pancreatic cancer and gemcitabine a primary agent for unresectable or metastatic pancreatic cancer, with 95% of the cost covered by national health insurance. Other drugs, including targeted agents, are not covered.
There were no differences in age, sex, stage, and extent of surgery between patients who did and did not receive adjuvant treatment (data not shown). Interestingly, the median survival of patients who received adjuvant chemoradiation was 20.8 months, higher than the 14.0 months for patients who did not receive adjuvant treatment. Despite nonrandomization of chemotherapy, its therapeutic effect remained significant for survival even after multivariate analysis. The benefits of adjuvant treatment were more prominent in the standard resection group (P = 0.016), with a 2-year survival rate of 50.7%, significantly higher than that of patients who did not receive adjuvant treatment (25.0%). However, adjuvant treatment had no effect on survival in the extended resection group. Extensive dissection around the pancreas may impair vascularity, reducing the postoperative effects of chemoradiation and increasing the likelihood of tumor spillage due to prolonged and extensive manipulation around the tumor. Indeed, we found that peritoneal seeding was significantly more frequent in the extended group (25.9%) than in the standard group (8.3%) (P = 0.011).
CONCLUSIONS
Extended pancreatectomy including extensive dissection of lymph nodes and the nerve plexus does not improve the long-term outcome of patients with pancreatic ductal adenocarcinoma. The early recovery and lower morbidity rate observed with standard pancreatic resection, followed by adjuvant treatment, suggest that this option enhances safety and efficacy in these patients.
